Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 2 September 1983:
Vol. 221. no. 4614, pp. 972 - 975
DOI: 10.1126/science.6136092
Prev | Table of Contents | Next

Articles

Science, Vol 221, Issue 4614, 972-975
Copyright © 1983 by American Association for the Advancement of Science

articles

Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia

CB Nemeroff, WW Youngblood, PJ Manberg, AJ Prange Jr, and JS Kizer

To ascertain whether Huntington's chorea and schizophrenia are associated with specific regional alterations in neurotensin, somatostatin, and thyrotropin-releasing hormone, the concentrations of these putative neurotransmitters were measured by radioimmunoassay in postmortem brain samples from patients with Huntington's chorea or schizophrenia. Compared to 50 patients without psychiatric or neurological disease, the patients with Huntington's chorea showed significantly elevated concentrations of all three neuropeptides in the nucleus caudatus. In the nucleus accumbens somatostatin levels were increased threefold, while in the amygdala thyrotropin-releasing hormone levels were elevated. In contrast, the schizophrenics exhibited reduced levels of thyrotropin-releasing hormone in two frontal cortical regions, reduced somatostatin levels in one frontal cortical area, and increased neurotensin levels in one frontal cortical area. None of the differences between the diseased brains and the controls could be accounted for by differences in age, sex, or time between death and autopsy.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Topical Review: Basal Ganglia: Functional Anatomy and Physiology. Part 1.
A. K. Afifi (1994)
J Child Neurol 9, 249-260
   Abstract »    PDF »
Merck, Sharp & Dohme Prize for Young Psychopharmacologists: A history of frontal and temporal lobe aspects of the neuropharmacology of schizophrenia.
R. Kerwin (1992)
J Psychopharmacol 6, 230-240
   Abstract »    PDF »
Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders.
A.J. Stoessl (1989)
J Psychopharmacol 3, 99-120
   PDF »
Alterations in Cerebrospinal Fluid Concentrations of Somatostatinlike Immunoreactivity in Neuropsychiatric Disorders.
G. Bissette, E. Widerlov, H. Walleus, I. Karlsson, K. Eklund, A. Forsman, and C. B. Nemeroff (1986)
Arch Gen Psychiatry 43, 1148-1151
   Abstract »    PDF »
Selective sparing of a class of striatal neurons in Huntington's disease.
R. Ferrante, N. Kowall, M. Beal, E. Richardson Jr, E. Bird, and J. Martin (1985)
Science 230, 561-563
   Abstract »    PDF »
Two types of somatostatin receptors differentiated by cyclic somatostatin analogs.
V. Tran, M. Beal, and J. Martin (1985)
Science 228, 492-495
   Abstract »    PDF »
Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases.
J. Greenamyre, J. Penney, A. Young, C. D'Amato, S. Hicks, and I Shoulson (1985)
Science 227, 1496-1499
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)